LAS VEGAS, NV, July 12, 2017 --
Praxsyn Corporation (OTCQB: PXYN) is pleased to announce that its wholly owned subsidiary pharmacy, Nevada Health Rx, Inc. (“NHRX”), located in Las Vegas, Nevada, is taking prescriptions on lien with home delivery for personal injury patients.
NHRX accepts and will provide prescriptions for people injured in a variety of ways with clear liability, including auto accidents, slip and fall injuries and dog bite cases which are just to name a few types of injuries in which NHRX will provide medications to patients on lien. Our home delivery and competitive pricing provides a valued service to the patient while they recover from their traumatic and often debilitating experience.
Praxsyn’s Chief Executive Officer, Greg Sundem, commented, “personal injury claims can be a very secure and lucrative market for our pharmacy division, and we have established internal systems to manage the collection process to ensure a profitable business line. I am pleased to be expanding our business in Nevada with additional licensing in other strategic markets”.
About Praxsyn Corporation
Headquartered in Las Vegas, Nevada, Praxsyn Corporation through its wholly owned subsidiaries Mesa Pharmacy and Nevada Health Rx, work to realize the vision of medical professionals to improve the lives of their patients. Additional company information can be found at www.praxsyn.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to statements in this press release regarding prescriptions on lien for personal injury patients, and thus accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports as have been filed with the Securities and Exchange Commission.
###
Media/Investor Contact: [email protected] 949-777-6112 ext. 101


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



